Exercise-induced bronchoconstriction: The effects of montelukast, a leukotriene receptor antagonist

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 923-934

  Kemp, James P ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Asthma; Bronchoconstriction; Bronchospasm; Exercise; Leukotrienes; Montelukast

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; HISTAMINE DERIVATIVE; LEUKOTRIENE DERIVATIVE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; MONTELUKAST; NEDOCROMIL; PLACEBO; SHORT ACTING DRUG; ZAFIRLUKAST; ZILEUTON;

AGGRESSION; AGITATION; ANXIETY; BEHAVIOR CHANGE; BRONCHOSPASM; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DEPRESSION; DRUG EFFICACY; DRUG RESEARCH; EXERCISE INDUCED ASTHMA; HALLUCINATION; HUMAN; IRRITABILITY; LIFESTYLE; MOOD CHANGE; RESTLESSNESS; REVIEW; SIDE EFFECT; SLEEP DISORDER; SUICIDAL IDEATION; SUICIDE; TREMOR; VIVID DREAM;

EID: 77949439021     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: 10.2147/tcrm.s4830     Document Type: Review

References (106)

1. Aretaeus. On the causes and symptoms of chronic diseases. In: Adams F, editor/translator. The Extant Works of Aretaeus the Cappadocian. London, UK: Syndenham Society; 1856. book I, chap XI. p. 316-318.
2. Anderson SD, Fitch K, Perry CP, et al. Responses to bronchial challenge submitted for approval to use inhaled beta2-agonists before an event at the 2002 Winter Olympics. J Allergy Clin Immunol. 2003;111:44-49.
3. Fitch KD, Sue-Chu M, Anderson SD, et al. Asthma and the elite athlete: summary of the International Olympic Committee's consensus conference, Lausanne, Switzerland, January 22-24, 2008. J Allergy Clin Immunol. 2008:122(2):254-260.
4. 2 agonists have an ergogenic potential in non-asthmatic competitive athletes? Sports Med. 2007;37(2):95-102.
5. World Anti-Doping Agency. The World Anti-Doping Code. The 2008 prohibited list: International standard. Available at: http://www.wada-ama. org/rtecontent/document/2008-List-En.pdf. Accessed on February 10, 2009.
6. Anderson SD, Sue-Chu M, Perry CP, et al. Bronchial challenges in athletes applying to inhale a beta 2-agonist at the 2004 Summer Olympics. J Allergy Clin Immunol. 2006;117:767-773.
7. Koh MS, Tee A, Lasserson TJ, Irving LB. Inhaled corticosteroids compared to placebo for prevention of exercised induce bronchoconstriction. Cochrane Database Syst Rev. 2007;3:CD002739.
8. McFadden ER. Approach to the patient exercise induced narrowing. In: Adkinson Jr NF, Yunginger JW, Busse WW, Bochner BS, Simons FER, Holgate ST, editors. Middleton's Allergy Principals and Practice. 7th Ed. Philadelphia, PA: Mosby; 2009. Chap 78. p. 1385.
9. Mussaffi H, Springer C, Godfrey S. Increased bronchial responsiveness to exercise and histamine after antigen challenge in children with asthma. J Allergy Clin Immunol. 1986;77:48-52.
10. Cabral AL, Conceicao GM, Fonseca-Guedes CH, et al. Exercise-induced bronchospasm in children: effects of asthma severity. Am J Respir Crit Care Med. 1999;159(6):1819-1823.
11. Turner SW, Young S, Goldblatt J, Landau LI, Le Souëf PN. Childhood asthma and increased airway responsiveness: a relationship that begins in infancy. Am J Respir Crit Care Med. 2009;179:98-104.
12. Deal EC Jr, McFadden ER Jr, Ingram RH Jr, Breslin FJ, Jaeger JJ. Airway responsiveness to cold air and hyperpnea in normal subjects and those with hay fever and asthma. Am Rev Respir Dis. 1980;121:621-628.
13. Turcotte H, Langdeau JB, Thibault G, Boulet LP. Prevalence of respiratory symptoms in an athlete population. Respir Med. 2003;97:955-963.
14. Kujuala UM, Sarna S, Kaprio J, Koskenvuo M. Asthma and other pulmonary diseases in former elite athletes. Thorax. 1996;51:288-292.
15. Eggleston PA, Guerrant JL. A standard method of evaluating exercise induced asthma. J Allergy Clin Immunol. 1976;58(3):414-425.
16. Pearlman DS, van Adelsberg J, Philip G, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Immunol. 2006;97:98-104.
17. Shturman-Ellstein R, Zeballos RJ, Buckley JM, et al. The beneficial effect of nasal breathing on exercise-induced bronchoconstriction. Am Rev Respir Dis. 1978;118:65-73.
18. Anderson SD, Argyros GJ, Magnussen H, Holzer K. Provocation by eucapnic voluntary hyperpnoea to identify exercise induced bronchoconstriction. Br J Sports Med. 2001;35(5):344-347.
19. Anderson SD Brannan JD. Methods for "indirect" challenge tests including exercise, eucapnic voluntary hyperpnea and hypertonic aerosols. Clin Rev Allergy Immunol. 2003;24(1):27-54.
20. Anderson SD. Exercise-induced asthma and the use of hypertonic saline aerosol as a bronchial challenge. Respirology. 1996;1(3):175-181.
21. Carlsen KH, Engh G, Mork M. Exercised-induced bronchoconstriction depends on exercise load. Respir Med. 2000;94(8):750-755.
22. McFadden ER Jr, Zawadski DK. Vocal cord dysfunction masquerading as exercise induced asthma. a physiologic cause for "choking" during athletic activities. Am J Respir Crit Care Med. 1996;153(3):942-947.
23. Ternesten-Hasséus E, Johansson EL, Bende M, Millqvist E. Dyspnea from exercise in cold air is not always asthma. J Asthma. 2008;45(8):705-709.
24. Teeter JG, Bleecher ER. Relationship between airway obstruction and respiratory symptoms in adult asthmatics. Chest. 1998;113(2):272-277.
25. Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000;161:309-329.
26. Holzer K, Anderson SD, Chan HK, Douglass J. Mannitol as a challenge test to identify exercise-induced bronchoconstriction in elite athletes. Am J Respir Crit Care Med. 2003;167(4):534-537.
27. Brannan JD, Koskela H, Anderson SD, Chew N. Responsiveness to mannitol in asthmatic subjects with exercise and hyperventilation-induced asthma. Am J Respir Crit Care Med. 1998;158(4):1120-1126.
28. McFadden ER Jr, Lenner KA, Strohl KP. Postexertional airway rewarming and thermally induced asthma. New insights into pathophysiology and possible pathogenesis. J Clin Invest. 1986;78:18-25.
29. Anderson SD, Daviskas E. The mechanism of exercise-induced asthma is... J Allergy Clin Immunol. 2000;106(3):453-459.
30. Anderson SD, Kippelen P. Airway injury as a mechanism for exercise-induced bronchoconstriction in elite athletes. J Allergy Clin Immunol. 2008;122(2):225-235.
31. Hallstrand TS, Moody MW, Aitken ML, Henderson WR Jr. Airway immunopathology of asthma with exercise-induced bronchoconstriction. J Allergy Clin Immunol. 2005;116(3):586-593.
32. Hallstrand TS, Moody MW, Wurfel MM, et al. Inflammatory basis of exercise- induced bronchoconstriction. Am J Respir Critical Care Med. 2005;172(6):679-686.
33. Helenius I, Haahtela T. Allergy and asthma in elite summer sport athletes. J Allergy Clin Immunol. 2000;106:444-452.
34. Uyan ZS, Carro S, Piacentini G, Bardaldi E. Swimming pool, respiratory health, and childhood asthma: should we change our beliefs? Pediatr Pulmonol. 2009;44(1):31-37.
35. Turcotte H, Langdeau JB, Thibault G, Boult LP. Prevalence of respiratory symptoms in an athletic population. Respir Med. 2003;97:995-963.
36. Helenius I, Lumme A, Haahtela T. Asthma airway inflammation and treatment in elite athletes. Sports Med. 2005;35:565-574.
37. Langdeau JB, Turcotte H, Bowie DM, et al. Airway hyperresponsiveness in elite athletes. Am J Respir Crit Care Med. 2000;161(5):1479-1484.
38. Carlsen KH, Anderson SD, Bjermer L, et al. Respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: Part 1 of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical immunology (EAACI) in cooperation with GA2LEN. Allergy. 2008;63(4):387-403.
39. Langdeau JB, Day A, Turcotte H, Boulet LP. Gender differences in the prevalence of airway hyperresponsiveness and asthma in athletes. Respir Med. 2009;103(3):401-406.
40. Bonsignore MR, La Gutta S, Cibella F, et al. Effects of exercise training and montelukast in children with mild asthma. Med Sci Sports Exerc. 2008;40(3):405-412.
41. Edmunds AT, Tooley M, Goodfrey S. The refractory period after exercise-induced asthma: its duration and relationship to the severity of exercise. Am Rev Respir Dis. 1978;117:247-254.
42. Bar-Yishay E, Ben-Dov I, Godfrey S. Refractory period after hyperventilation induced asthma. Am Rev Respir Dis. 1983;127:572-574.
43. Mickleborough TD, Lindley MR, Turner LA. Comparative effect of a high-intensity interval warm-up and salbutamol on the bronchoconstrictor response to exercise in asthmatic athletes. Int J Sports Med. 2007;28(6):456-462.
44. Cabral AL, Conceicao CM, Fonsecca-Guedes CM, Martins MA. Exercise-induced bronchospasm in children: effects of asthma severity. Am J Respir Crit Care Med. 1999;159:1819-1823.
45. National Institutes of Health. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. NIH Publication No.08-4051. Bethesda MD: US Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood Institute, National Asthma Education and Prevention Program;August 2007.
46. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143-178.
47. Garcia-Aymerich J, Varraso R, Anto JM, Carmarargo Jr CA. Prospective study of physical activity and risk of asthma exacerbations in older women. Am J Respir Crit Care Med. 2009;179:999-1003.
48. Lima JJ, Blake KV, Tantisira KG, Weiss ST. Pharmacogenetics of asthma. Curr Opin Pulm Med. 2009;15(1):57-62.
49. Israel E. Genetics and variability of treatment responses in asthma. J Allergy Clin Immunol. 2005;115(4 Suppl):S532-S538.
50. Hartley JP, Davies BH. Cholinergic blockade in the prevention of exercise-induced asthma. Thorax. 1980;35(9):680-685.
51. Poppius H, Sovijärvi AR, Tammilehto L. Lack of protective effect of high-dose ipratropium on bronchoconstriction following exercise with cold air breathing in patients with mild asthma. Eur J Respir Dis. 1986;68(5):319-325.
52. Pasterkamp H, Tal A, Leahy F, Fenton R, Chernick V. The effect of anticholinergic treatment on postexertional wheezing in asthma studied by phonopneumography and spirometry. Am Rev Respir Dis. 1985;132(1):16-21.
53. Larsson K. Oxitropium bromide, ipratropium bromide and fenoterol in exercise-induced asthma. Respiration. 1982;43(1):57-63.
54. Koh MS, Tee A, Lasserson TJ, Irving LB. Inhaled corticosteroids compared to placebo for prevention of exercise induced bronchoconstriction. Cochrane Database Syst Rev. 2007;3:CD002739.
55. Kelloway JS, Wyatt RA, Adlis SA. Comparison of patient's compliance with prescribed oral and inhaled asthma medications. Arch Intern Med. 1994;154:1349-1352.
56. Smith BW, LaBotz M. Pharmacologic treatment of exercise induced asthma. Clin Sports Med. 1998;17:343-336.
57. Anderson SD. Single-dose agents in the prevention of exercise-induced asthma: a descriptive review. Treat Respir Med. 2004;3:365-379.
58. Anderson SD, Brannan JD. Long-acting beta 2-adrenoceptor agonists and exercise-induced asthma: lessons to guide us in the future. Paediatr Drugs. 2004;6(3):161-175.
59. Anderson SD, Rodwell LT, Du Toit J, et al. Duration of protection by inhaled salmeterol in exercise-induced asthma. Chest. 1991;100:1254-1260.
60. Nelson JA, Strauss L, Skowronski M, et al. Effect of long-term salmeterol treatment on exercise-induced asthma. N Engl J Med. 1998;339:141-146.
61. Boner AL, Spezia E, Piovesan P, et al. Inhaled formoterol in the prevention of exercise induced bronchoconstriction in asthmatic children. Am J Respir Crit Care Med. 1994;149:935-939.
62. McAlpine LG, Thomson NC. Prophylaxis of exercise-induced asthma with inhaled formoterol, a long-acting beta 2-adrenergic agonist. Respir Med. 1990;84:293-295.
63. Simons EF, Gerstner TV, Cheang MS. Tolerance to the bronchoprotective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics. 1997;99:655-659.
64. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced bronchospasm after chronic dosing with salmeterol. Respir Med. 1994;88:363-368.
65. Castle W, Fuller R, Hall J, et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. Br Med J. 1993;306:1034-1037.
66. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM; SMART Study Group. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006;129:15-26.
67. Summary minutes of the joint pulmonary-allergy drugs advisory committee (PADAC), drug safety and risk management advisory committee (DSaRM) and pediatric advisory committee (PAC). 2008. Dec 10-11, http://www.fda.gov/ohrms/ ac/08/minutes/2008-4398m1-final.pdf.
68. Sears MR, Ottosson A, Radner F, Swissa S. Long-acting beta-agonists: a review of formoterol safety data from asthma clinical trials. Eur Respir J. 2009;33:21-32.
69. Morton AR, Ogle SL, Fitch KD. Effects of nedocromil sodium, cromolyn sodium, and a placebo in exercise-induced asthma. Ann Allergy. 1992;68(2):143-148.
70. Spooner C, Rowe BH, Sanders LD. Nedocromil sodium in the treatment of exercise-induced asthma: a meta-analysis. Eur Respir J. 2000;16(1):30-37.
71. Spooner CH, Spooner GR, Rowe BH. Mast-cell stabilizing agents to prevent exercise induced bronchoconstriction. Cochrane Database Syst Rev. 2003;4:CD002307.
72. Israel E, Drazen JM. Role of 5-lipoxygenase metabolites of arachidonic acid in exercise-induced asthma. In: McFadden ER Jr, editor. Exercise-induced Asthma. Vol. 130. New York. NY: Marcel Dekker, Inc; 1999. p.167-180.
73. O'Byrne PM. Leukotriene bronchoconstriction induced by allergen and exercise. Am J Respir Crit Care Med. 2000;161:S68-S72.
74. Bisgaard H. Role of leukotrienes in asthma pathology. Pediatr Pulmonol. 2000;30;166-176.
75. Philip G, Pearlman DS, Villaran C, et al. Protection against exercise-induced bronchoconstriction by a single, oral dose of montelukast. J Asthma. 2007;44:213-217.
76. Pearlman DS, van Adelsberg J, Philip G, et al. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol. 2006;97:98-104.
77. Kemp JP. Role of leukotriene receptor antagonists in pediatric asthma. Pediatr Pulmonol. 2000;30(2):177-182.
78. Manning PJ, Watson RM, Margolskee DJ, et al. Inhibition of exercise-induced bronchoconstriction by MK-571, a potent leukotriene D4-receptor antagonist. N Engl J Med. 1990;323:1736-1739.
79. Lehnigk B, Rabe KF, Dent G, et al. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. Eur Respir J. 1998;11:617-623.
80. Meltzer SS, Hasday JD, Cohn J, et al. Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med. 1996;153:931-935.
81. Dessanges JF, Prefaut C, Taytard A, et al. The effect of zafirlukast on repetitive exercise induced bronchoconstriction: the possible role of leukotrienes in exercise-induced refractoriness. J Allergy Clin Immunol. 1999;104:1155-1161.
82. Pearlman DS, Ostrom NK, Bronsky EA, et al. The leukotriene D4-receptor antagonist zaf irlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr. 1999;134:273-279.
83. Suguro H, Majima T, Hattori T, et al. [Effect of a leukotriene antagonist, pranlukast hydrate, on exercise-induced asthma for 14 days]. Arerugi. 2000;49(8):646-652.
84. Zhao JJ, Rogers JD, Holland SD, et al. Pharmacokinetics and bioavailability of montelukast sodium (MK-0476) in healthy young and elderly volunteers. Biopharm Drug Dispos. 1997;18:769-777.
85. Leff JA, Busse WW, Pearlman DS, Bronsky EA, Kemp JP. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med. 1998;339:147-152.
86. Kemp JP, Dockhorn RJ. Shapiro GG, et al. Montelukast once daily inhibits exercise-induced bronchoconstriction in 6-14 year-old children with asthma. J Pediatrics. 1998:133(3):424-428.
87. Pradalier A. Late phase reaction in asthma: Basic mechanisms. Int Arch Allergy Immunol. 1993;101(3):322-325.
88. Verhoeff NP, Speelberg B, van den Berg NJ, Oosthoek CH, Stijnen T. Real and pseudo late asthmatic reactions after submaximal exercise challenge in patients with bronchial asthma. A new definition for late asthmatic responses after exercise challenge. Chest. 1990;98:1194-1199.
89. Karjalainen J. Exercise response in 404 young men with asthma: no evidence of a late asthmatic reaction. Thorax. 1991;46:100-104.
90. Lee TH, Nagukura T, Papageorgiou N, Tikura Y, Kay AB. Exercise induced late asthmatic reaction with chemotactic activity. N Engl J Med. 1983;308(25):1502-1505.
91. Boulet LP, Legris C, Turcotte H, Hebert J. Prevalence and characteristics of late asthmatic responses to exercise . J Allergy Clin Immunol. 1987;80(5):655-662.
92. Mello RE, Sole D, Naspitz CK. Exercise-induced bronchoconstriction in Children: Montelukast attenuates the immediate-phase and late-phase responses. J Allergy Clin Immunol. 2003;111(2); 301-307.
93. Booth H, Bish R, Walters J, Whitehead F, et al. Salmeterol tachyphylaxis in steroid treated subjects. Thorax. 1996;51(11):1100-1104.
94. Garcia R, Garcia P, Feo F, et al. Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm. J Investig Allergol Clin Immunol. 2001;11:176-182.
95. Edelman JM, Turpin JA, Bronsky EA, Grossman J, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise induced bronchoconstriction. Ann Intern Med. 2000;132:97-104.
96. Storms W, Chervinsky P, Ghannam AF, Bird S, Hustad CM, Edelman JM; Challenge-Rescue Study Group. A comparison of the effects of oral montelukast and inhaled salmeterol on response to rescue bronchodilation after challenge. Respir Med. 2004;98(11):1051-1062.
97. de Benedictis FM, Del Giudice MM, Forenza N, et al. Lack of tolerance to the protective effect of montelukast in exercise-induced bronchoconstriction in children. Eur Respir J. 2006;28:291-295.
98. Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med. 1999;130(6):487-495.
99. Szefler SJ, Baker JW, Uryniak T, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with asthma. J Allergy Clin Immunol. 2007;120(5):1043-1050.
100. Helenius I, Lumme A, Ounap J, et al. No effect of montelukast on asthma-like symptoms in elite ice hockey players. Allergy. 2004;59(1):39-44.
101. Kang MJ, Lee SY, Kim HB, et al. Association of IL-13 polymorphisms with leukotriene receptor antagonist drug responsiveness in Korean children with exercise-induced bronchoconstriction. Pharmacogenet Genomics. 2008;18(7):551-558.
102. Kim JH, Lee SY, Kim HB, et al. TBXA2R gene polymorphism and responsiveness to leukotriene receptor antagonist in children with asthma. Clin Exp Allergy. 2008;38(1):51-59.
103. Guilpain P, Pagnoux C, Lhote F, Mouthon L, Guillevin L. Anti-leukotrienes and Churg - Strauss syndrome. Presse Med. 2007;36(5 Pt 2):890-894.
104. Wechsler ME, Finn D, Gunawardena D, et al. Churg - Strauss syndrome in patients receiving montelukast as treatment for asthma. Chest. 2000;117(3):708-713.
105. Nathani N, Little MA, Kunst H, Wilson D, Thickett DR. Churg - Strauss syndrome and leukotriene antagonist use: a respiratory perspective. Thorax. 2008;63(10):883-888.
106. US Food and Drug Administration. FDA requests labeling change for leukotriene modifiers. June 12, 2009. Available from: http://www.fda.gov/ NewsEvents/Newsroom/PressAnnouncements/ucm166293.htm. Accessed on July 10, 2009.